{"schema_version":"secwatch.filing_event.v1","accession":"0001321732-24-000058","form_type":"8-K","ticker":"PEN","cik":"0001321732","company_name":"Penumbra Inc","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.831626+00:00","generated_at":"2026-06-02T16:45:21.983363+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Penumbra Q1 revenue $278.7M (+15.4% YoY); U.S. thrombectomy up 35.2%; reaffirms FY24 guidance","bullets":["Revenue $278.7M, up 15.4% YoY (15.2% constant currency); U.S. thrombectomy $150.3M, +35.2%.","GAAP operating income $12.1M vs $8.0M YoY; non-GAAP operating income $19.3M.","Adjusted EBITDA $37.6M (13.5% margin); cash & investments rose $24.3M sequentially.","FY2024 guidance reaffirmed: total revenue growth 16-20%, U.S. thrombectomy growth 27-30%.","Gross margin improved to 65.0% from 62.6% on favorable product mix and productivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001321732-24-000058","json":"https://secwatch.observer/filing/0001321732-24-000058.json","markdown":"https://secwatch.observer/filing/0001321732-24-000058.md","text":"https://secwatch.observer/filing/0001321732-24-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321732/000132173224000058/0001321732-24-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321732/000132173224000058/pen-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:45:21.983363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8e74ac543ee5068a1c598fa503ffb4562ca6f5c","claim":"Penumbra Inc reported the first fiscal quarter ended March 31, 2024 results: revenue $278.7 million. Guidance reaffirmed.","evidence_excerpt":"Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024. • Revenue of $278.7 million in the first quarter of 2024, an increase of 15.4% or 15.2% in constant currency 1 , compared to the first quarter of 2023. • U.S. thrombectomy revenue of $150.3 million in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1321732/000132173224000058/0001321732-24-000058-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first fiscal quarter ended March 31, 2024"},{"label":"Revenue","value":"$278.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}